Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
Promberger R, Dubsky P, Mittlböck M, Ott J, Singer C, Seemann R, Exner R, Panhofer P, Steger G, Bergen E, Gnant M, Jakesz R, Bago-Horvath Z, Rudas M, Bartsch R.
Promberger R, et al. Among authors: ott j.
Clin Breast Cancer. 2015 Dec;15(6):505-11. doi: 10.1016/j.clbc.2015.06.007. Epub 2015 Jun 18.
Clin Breast Cancer. 2015.
PMID: 26195436